Moreover, in vivo therapeutic delivery of miR‐520d‐3p mimic and EphA2 siRNA induced potent synergy, resulting in substantial inhibition of tumor growth when compared with individual treatments in ovarian cancer tumor xenograft models (Nishimura et al., 2013). The gene discussed is EPHA2; the disease is ovarian cancer.